Government-Owned Inventions; Availability for Licensing, 6879-6880 [2022-02466]

Download as PDF Federal Register / Vol. 87, No. 25 / Monday, February 7, 2022 / Notices Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827–4471, ramadanir@ mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: February 1, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–02469 Filed 2–4–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings jspears on DSK121TN23PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT). Date: March 9, 2022. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W140, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: David G. Ransom, Ph.D., Chief, Scientific Review Officer, Special VerDate Sep<11>2014 17:36 Feb 04, 2022 Jkt 256001 Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W140, Rockville, Maryland 20850, 240–276–6351, david.ransom@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; The Role of Epstein Barr Virus (EBV) Infection in NonHodgkin Lymphoma (NHL) and Hodgkin Disease (HD) Development with or without an Underlying HIV Infection (U01). Date: March 24, 2022. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W104, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Robert F. Gahl, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9606 Medical Center Drive, Room 7W104, Rockville, Maryland 20850, 240–276–7869, robert.gahl@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; R13 Conference Grant Review. Date: March 24, 2022. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W552, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Jeanette Irene Marketon, Ph.D., Scientific Review Officer, Program Coordination and Referral Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W552, Rockville, Maryland 20850, 240–276–6780, jeanette.marketon@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; TEP–11: SBIR Contract Review Meeting. Date: March 31, 2022. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W126, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Susan Lynn Spence, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W126, Rockville, Maryland 20850, 240–620–0819, susan.spence@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Center Support Grant. Date: May 12, 2022. Time: 2:00 p.m. to 3:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: CAPT Shari Williams Campbell, DPM, MSHS, Scientific Review PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 6879 Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850, 240–276–7381, shari.campbell@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: February 2, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–02476 Filed 2–4–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240–669–5299; elizabeth.pitts@nih.gov. Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows: SUMMARY: Monoclonal Antibodies To Prevent or Treat SARS–CoV–2 Infection Description of Technology The ongoing COVID–19 pandemic, caused by severe respiratory syndrome coronavirus 2 (SARS–CoV–2), has E:\FR\FM\07FEN1.SGM 07FEN1 6880 Federal Register / Vol. 87, No. 25 / Monday, February 7, 2022 / Notices created an immense public health, social, and economic burden. Variants of concern continue to emerge that have increased transmissibility, pathogenicity, or both and that reduce the effectiveness of current therapeutics and vaccines. Thus, there is a great need for broadly protective therapeutics. This technology relates to two monoclonal antibodies targeting the spike protein of SARS–CoV–2 that between the two have picomolar activity against wild-type SARS–CoV–2 and the Alpha, Beta, Delta, and Omicron variants of concern. Additionally, one of the antibodies recognizes a highlyconserved epitope of the spike protein. Treatment with either monoclonal antibody before or after challenge with SARS–CoV–2 reduced symptoms and viral load in nasal turbinate and lung tissue in the golden Syrian hamster model. This monoclonal antibody technology has great potential to treat SARS–CoV–2 infections and may provide protection against future variants of concern. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404. Potential Commercial Applications • Treatment for SARS–CoV–2 infection • Prophylaxis treatment to prevent or reduce SARS–CoV–2 infection • Diagnostic for SARS–CoV–2 infection Competitive Advantages • Broad and potent neutralization of several variants of concern, including Omicron jspears on DSK121TN23PROD with NOTICES1 Development Stage • In vivo data assessment (animal) Inventors: Zhaochun Chen (NIAID); Patrizia Farci (NIAID); Kamille West (CC); Peng Zhang (NIAID); Paolo Lusso (NIAID); Ulla Buchholz (NIAID); Yumiko Matsuoka (NIAID). Intellectual Property: HHS Reference No. E–132–2021– U.S. Provisional Application No. 63/296,380, filed January 4, 2022. Licensing Contact: To license this technology, please contact Elizabeth Pitts, Ph.D., 240–669–5299; elizabeth.pitts@nih.gov, and reference E–132–2021. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology. For collaboration opportunities, please contact Elizabeth Pitts, Ph.D., 240–669– 5299; elizabeth.pitts@nih.gov. VerDate Sep<11>2014 17:36 Feb 04, 2022 Jkt 256001 Dated: February 1, 2022. Surekha Vathyam, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2022–02466 Filed 2–4–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; NST 1 Member SEP. Date: March 1, 2022. Time: 9:00 a.m. to 12:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: William C. Benzing, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS, NIH, NSC, 6001 Executive Boulevard, Suite 3204, MSC 9529, Rockville, MD 20852, 301–496–0660, benzingw@ mail.nih.gov. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; BRAIN Initiative: TeamResearch BRAIN Circuit Programs U19 Review. Date: March 8–11, 2022. Time: 10:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Tatiana Pasternak, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Suite 3208, MSC 9529, Rockville, MD 20852, 301–496–9223, tatiana.pasternak@nih.gov. PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Biomarkers for the Lewy Body Dementias. Date: March 11, 2022. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Joel A. Saydoff, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Boulevard, Room 3205, MSC 9529, Rockville, MD 20852, 301–496–9223, joel.saydoff@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: February 1, 2022. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–02468 Filed 2–4–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Federal Emergency Management Agency [Docket ID FEMA–2020–0016] Plan of Action To Establish a National Strategy for the Coordination of National Multimodal Healthcare Supply Chains To Respond to COVID–19; Implemented Under the Voluntary Agreement for the Manufacture and Distribution of Critical Healthcare Resources Necessary To Respond to a Pandemic Under Section 708 of the Defense Production Act Federal Emergency Management Agency, Department of Homeland Security. ACTION: Notice. AGENCY: The Federal Emergency Management Agency (FEMA) is publishing the text of one additional Plan of Action under the Voluntary Agreement for the Manufacture and Distribution of Critical Healthcare Resources Necessary to Respond to a Pandemic: Plan of Action to Establish a National Strategy for the Coordination of National Multimodal Healthcare Supply Chains to Respond to COVID– 19. SUMMARY: FOR FURTHER INFORMATION CONTACT: Robert Glenn, Office of Business, E:\FR\FM\07FEN1.SGM 07FEN1

Agencies

[Federal Register Volume 87, Number 25 (Monday, February 7, 2022)]
[Notices]
[Pages 6879-6880]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-02466]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Elizabeth Pitts, Ph.D., 240-669-5299; 
[email protected]. Licensing information and copies of the patent 
applications listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement may be required to receive any 
unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows:

Monoclonal Antibodies To Prevent or Treat SARS-CoV-2 Infection

Description of Technology

    The ongoing COVID-19 pandemic, caused by severe respiratory 
syndrome coronavirus 2 (SARS-CoV-2), has

[[Page 6880]]

created an immense public health, social, and economic burden. Variants 
of concern continue to emerge that have increased transmissibility, 
pathogenicity, or both and that reduce the effectiveness of current 
therapeutics and vaccines. Thus, there is a great need for broadly 
protective therapeutics.
    This technology relates to two monoclonal antibodies targeting the 
spike protein of SARS-CoV-2 that between the two have picomolar 
activity against wild-type SARS-CoV-2 and the Alpha, Beta, Delta, and 
Omicron variants of concern. Additionally, one of the antibodies 
recognizes a highly-conserved epitope of the spike protein. Treatment 
with either monoclonal antibody before or after challenge with SARS-
CoV-2 reduced symptoms and viral load in nasal turbinate and lung 
tissue in the golden Syrian hamster model. This monoclonal antibody 
technology has great potential to treat SARS-CoV-2 infections and may 
provide protection against future variants of concern.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications

 Treatment for SARS-CoV-2 infection
 Prophylaxis treatment to prevent or reduce SARS-CoV-2 
infection
 Diagnostic for SARS-CoV-2 infection

Competitive Advantages

 Broad and potent neutralization of several variants of 
concern, including Omicron

Development Stage

     In vivo data assessment (animal)
    Inventors: Zhaochun Chen (NIAID); Patrizia Farci (NIAID); Kamille 
West (CC); Peng Zhang (NIAID); Paolo Lusso (NIAID); Ulla Buchholz 
(NIAID); Yumiko Matsuoka (NIAID).
    Intellectual Property: HHS Reference No. E-132-2021- U.S. 
Provisional Application No. 63/296,380, filed January 4, 2022.
    Licensing Contact: To license this technology, please contact 
Elizabeth Pitts, Ph.D., 240-669-5299; [email protected], and 
reference E-132-2021.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this technology. For collaboration 
opportunities, please contact Elizabeth Pitts, Ph.D., 240-669-5299; 
[email protected].

    Dated: February 1, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-02466 Filed 2-4-22; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.